---
title: "Galectin, FDA agree on late-stage trial design for MASH therapy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290567199.md"
description: "Galectin Therapeutics (GALT) announced an agreement with the FDA on the design and primary endpoint for a Phase 3 trial of belapectin for MASH-related cirrhosis. This follows the failure of its NAVIGATE Phase 2b/3 trial in 2024. Despite the regulatory progress, GALT shares fell ~9% premarket. The company expects the new study to be comparable in size to NAVIGATE, with a final protocol submission anticipated in Q3 2026."
datetime: "2026-06-23T13:00:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290567199.md)
  - [en](https://longbridge.com/en/news/290567199.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290567199.md)
generator: "portal-rs"
---

# Galectin, FDA agree on late-stage trial design for MASH therapy


### Related Stocks

- [GALT.US](https://longbridge.com/en/quote/GALT.US.md)

## Related News & Research

- [Galectin Therapeutics to Present at H.C. Wainwright Global Investment Conference](https://longbridge.com/en/news/298591097.md)
- [Scholar Rock announces FDA approval of isembyld](https://longbridge.com/en/news/298786115.md)
- [X4 Pharma Reports Positive Outcome Of Type C Meeting With FDA Related To 4WARD Phase 3 Trial](https://longbridge.com/en/news/298310226.md)
- [Spectral Medical says FDA 100-day PMA review for Toraymyxin does not require new clinical trial](https://longbridge.com/en/news/298720796.md)
- [Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In](https://longbridge.com/en/news/298761132.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**